ArticleWorld journal of gastroenterology2013
Primary adenosquamous carcinoma of the esophagus.
Article in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Knowledge gaps in tubular gut tumours: a critical appraisal of the 6th edition of the World Health Organization classification of tumours.The Journal of pathology · 2026Review
- Rare Gastroesophageal Tumor Subtypes: Clinicopathologic Characteristics, Molecular Alterations, and Therapeutic Implications.Cancers · 2026Review
- Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system.Histopathology · 2026Review
- The Worst of Both Worlds: A Case Series of Adenosquamous Carcinoma of the Esophagus.ACG case reports journal · 2026Article
- Adenosquamous Carcinoma in Barrett's Esophagus: A Rare Entity.GE Portuguese journal of gastroenterology · 2025Review
- The Impact of Tumor Stage and Histopathology on Survival Outcomes in Esophageal Cancer Patients over the Past Decade.Medical sciences (Basel, Switzerland) · 2024Article
- Analysis of clinicopathological characteristics and prognosis on primary gastric adenosquamous carcinoma.Scientific reports · 2024Article
- Occurrence and Prognosis of Mixed Subtype Adenocarcinoma and Adeno-Squamous Carcinoma in Esophageal Cancer.Journal of Cancer · 2024Article
- Clinical-Pathological Characteristics of Adenosquamous Esophageal Carcinoma: A Propensity-Score-Matching Study.Journal of personalized medicine · 2023Article
- Surgical resection for esophageal adenosquamous carcinoma: an analysis of 56 cases.World journal of surgical oncology · 2022Article
- A case report of adenosquamous carcinoma of the esophagogastric junction.Surgical case reports · 2022Article
- A long-term survival case with recurrent esophageal adenosquamous carcinoma.International cancer conference journal · 2021Article
- Clinical Characteristics, Prognosis, and Nomogram for Esophageal Cancer Based on Adenosquamous Carcinoma: A SEER Database Analysis.Frontiers in oncology · 2021Article
- Neoplastic and pre-neoplastic lesions of the oesophagus and gastro-oesophageal junction.Pathologica · 2020Review
- Histopathological landscape of rare oesophageal neoplasms.World journal of gastroenterology · 2020Review
- Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma.American journal of clinical oncology · 2019Article
- Adenosquamous Carcinoma of the Esophagus: A Literature Review.Journal of translational internal medicine · 2018Article
- Esophageal adenosquamous carcinoma mimicking acantholytic squamous cell carcinoma.Oncology letters · 2017Article
- Pancreatic adenosquamous carcinoma and intraductal papillary mucinous neoplasm in aWorld journal of gastrointestinal oncology · 2017Article
- Clinical characteristics of adenosquamous esophageal carcinoma.Journal of gastrointestinal oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the clinical characteristics, diagnosis, treatment, and prognosis of primary adenosquamous carcinoma (ASC) of the esophagus.
methodsA total of 4015 patients with esophageal carcinoma underwent surgical resection between January 1995 and June 2012 at the Cancer Hospital of Shantou University Medical College. In 37 cases, the histological diagnosis was primary ASC. Clinical data were retrospectively analyzed from these 37 patients, who underwent transthoracic esophagectomy with lymphadenectomy. The χ(2) or Fisher's exact test was used to compare the clinicopathological features between patients with ASC and those with squamous cell carcinoma (SCC). The Kaplan-Meier and Log-Rank methods were used to estimate and compare survival rates. A Cox proportional hazard regression model was used to identify independent prognostic factors.
resultsPrimary esophageal ASC accounted for 0.92% of all primary esophageal carcinoma cases (37/4015). The clinical manifestations were identical to those of other types of esophageal cancer. All of the 24 patients who underwent preoperative endoscopic biopsy were misdiagnosed with SCC. The median survival time (MST) was 21.0 mo (95%CI: 12.6-29.4), and the 1-, 3-, and 5-year overall survival rates were 67.5%, 29.4%, and 22.9%, respectively. In multivariate analysis, only adjuvant radiotherapy (HR = 0.317, 95%CI: 0.114-0.885, P = 0.028) was found to be an independent prognostic factor. The MST for ASC patients was significantly lower than that for SCC patients [21.0 mo (95%CI: 12.6-29.4) vs 46.0 mo (95%CI: 40.8-51.2), P = 0.001]. In subgroup analyses, the MST for ASC patients was similar to that for poorly differentiated SCC patients.
conclusionPrimary esophageal ASC is a rare disease that is prone to be misdiagnosed by endoscopic biopsy. The prognosis is poorer than esophageal SCC but similar to that for poorly differentiated SCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.